Indivior (NASDAQ:INDV) Downgraded to “Hold” Rating by Zacks Research

Indivior (NASDAQ:INDV) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. Morgan Stanley restated an “overweight” rating and set a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Craig Hallum reiterated a “buy” rating and issued a $41.00 price target on shares of Indivior in a research report on Friday, October 31st. Piper Sandler reissued an “overweight” rating and set a $41.00 price objective (up from $27.00) on shares of Indivior in a research note on Friday, October 31st. Finally, HC Wainwright upped their target price on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.57.

Indivior Trading Down 1.1%

INDV stock opened at $33.63 on Tuesday. The firm has a 50 day moving average of $34.30 and a 200-day moving average of $26.39. The company has a market cap of $4.20 billion, a price-to-earnings ratio of 36.55 and a beta of 0.75. Indivior has a 12-month low of $7.62 and a 12-month high of $38.00.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.34. The firm had revenue of $314.00 million during the quarter, compared to the consensus estimate of $257.66 million. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%. Sell-side analysts forecast that Indivior will post 1.22 earnings per share for the current fiscal year.

Insider Transactions at Indivior

In other Indivior news, Director Keith Humphreys bought 775 shares of Indivior stock in a transaction that occurred on Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the transaction, the director owned 5,802 shares of the company’s stock, valued at $205,332.78. This represents a 15.42% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Barbara Ryan purchased 775 shares of the stock in a transaction on Monday, January 5th. The stock was acquired at an average price of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director directly owned 1,963 shares in the company, valued at $69,470.57. This trade represents a 65.24% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 4,871 shares of company stock valued at $172,385.

Hedge Funds Weigh In On Indivior

A number of hedge funds have recently made changes to their positions in INDV. Goldman Sachs Group Inc. grew its stake in shares of Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after buying an additional 1,299,425 shares during the period. Jane Street Group LLC grew its position in Indivior by 2,597.9% during the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after acquiring an additional 958,132 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Indivior by 16.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after acquiring an additional 666 shares during the period. State of New Jersey Common Pension Fund D acquired a new stake in Indivior during the second quarter worth about $262,000. Finally, Y Intercept Hong Kong Ltd raised its holdings in shares of Indivior by 17.4% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock worth $375,000 after purchasing an additional 3,769 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.